We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: immunotherapy
MedXY News
EnglishTag

immunotherapy

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Optimizing Immunotherapy in Cholangiocarcinoma: Low-Dose Chemotherapy as a Catalyst for Immune Microenvironment Remodeling
Clinical UpdatesCholangiocarcinomaimmunotherapy

Optimizing Immunotherapy in Cholangiocarcinoma: Low-Dose Chemotherapy as a Catalyst for Immune Microenvironment Remodeling

By MedXY|Mar 7, 2026

This review examines how low-dose gemcitabine and cisplatin (LDGC) synergize with anti-PD-L1 therapy in intrahepatic cholangiocarcinoma by reprogramming immunosuppressive SPP1+ macrophages and enhancing CD8+ T-cell cytotoxicity through STAT

SURE-02 Trial: Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Enable Bladder Preservation in Muscle-Invasive Disease
newsantibody-drug conjugatesimmunotherapy

SURE-02 Trial: Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Enable Bladder Preservation in Muscle-Invasive Disease

By MedXY|Mar 4, 2026

The SURE-02 phase 2 trial demonstrates that a combination of sacituzumab govitecan and pembrolizumab achieves a 39% clinical complete response rate in muscle-invasive bladder cancer, offering a promising bladder-sparing alternative for pati

Three-Year RATIONALE-309 Data Confirm Sustained Survival Benefit of First-Line Tislelizumab in Nasopharyngeal Carcinoma
newsimmunotherapynasopharyngeal carcinoma

Three-Year RATIONALE-309 Data Confirm Sustained Survival Benefit of First-Line Tislelizumab in Nasopharyngeal Carcinoma

By MedXY|Mar 2, 2026

Long-term results from the RATIONALE-309 trial show tislelizumab plus chemotherapy significantly improves survival in recurrent or metastatic nasopharyngeal carcinoma, establishing a durable therapeutic standard and identifying B-cell signa

KEYVIBE-010: Why Adding TIGIT Inhibition to Pembrolizumab Failed to Benefit High-Risk Resected Melanoma Patients
Dermatologyimmunotherapymelanoma

KEYVIBE-010: Why Adding TIGIT Inhibition to Pembrolizumab Failed to Benefit High-Risk Resected Melanoma Patients

By MedXY|Mar 2, 2026

The Phase 3 KEYVIBE-010 trial demonstrates that adding vibostolimab to pembrolizumab in the adjuvant setting for melanoma does not improve outcomes, instead yielding a higher recurrence rate and increased toxicity, reinforcing pembrolizumab

Redefining the Standard of Care in High-Risk Resected SCCHN: Insights from the GORTEC 2018-01 NIVOPOST-OP Trial
Clinical Updateshead and neck cancerimmunotherapy

Redefining the Standard of Care in High-Risk Resected SCCHN: Insights from the GORTEC 2018-01 NIVOPOST-OP Trial

By MedXY|Mar 2, 2026

This review analyzes the Phase 3 NIVOPOST-OP trial, demonstrating that adding nivolumab to postoperative chemoradiotherapy significantly improves disease-free survival in high-risk SCCHN patients, establishing a potential new therapeutic st

Pembrolizumab Dominates the HNC Market While Immune-Related Adverse Events Persist in Real-World Practice
newsadverse eventshead and neck cancer

Pembrolizumab Dominates the HNC Market While Immune-Related Adverse Events Persist in Real-World Practice

By MedXY|Feb 19, 2026

A large-scale cohort study of 47,365 head and neck cancer patients reveals a significant market shift toward pembrolizumab and a 41.2% incidence of immune-related adverse events, though severe toxicities remain rare and are linked to specif

Serplulimab Plus Chemotherapy Redefines First-Line Standards in Non-Squamous NSCLC: Results from the ASTRUM-002 Trial
newsclinical trialsimmunotherapy

Serplulimab Plus Chemotherapy Redefines First-Line Standards in Non-Squamous NSCLC: Results from the ASTRUM-002 Trial

By MedXY|Feb 19, 2026

The Phase 3 ASTRUM-002 trial demonstrates that adding serplulimab to chemotherapy significantly extends progression-free survival in non-squamous NSCLC, though the further addition of a bevacizumab biosimilar (HLX04) did not provide statist

Personalised T-Cell Activation Shows Promise in Overcoming Minimal Residual Disease in Chronic Lymphocytic Leukaemia
Hematology-OncologyChất ức chế BTKCLL

Personalised T-Cell Activation Shows Promise in Overcoming Minimal Residual Disease in Chronic Lymphocytic Leukaemia

By MedXY|Feb 19, 2026

A Phase 1 study demonstrates that iTAC-XS15-CLL01, a personalised multipeptide T-cell activator, induces robust immune responses in 95% of CLL patients on BTK inhibitors, offering a potential path to sustainable cancer control and eradicati

Breaking Resistance in Gynaecological Clear Cell Carcinoma: Pembrolizumab plus Lenvatinib Achieves 40% Response Rate in LARA Trial
newsangiogenesisimmunotherapy

Breaking Resistance in Gynaecological Clear Cell Carcinoma: Pembrolizumab plus Lenvatinib Achieves 40% Response Rate in LARA Trial

By MedXY|Feb 18, 2026

The Phase 2 LARA trial demonstrates that combining pembrolizumab and lenvatinib yields a 40% objective response rate in recurrent gynaecological clear cell carcinoma, offering a potential new standard for this historically chemo-resistant a

Fractionated Dosing of Varnimcabtagene Autoleucel Delivers Deep Remissions and Enhanced Safety in Adult B-ALL
Hematology-OncologyCAR T-cell therapyimmunotherapy

Fractionated Dosing of Varnimcabtagene Autoleucel Delivers Deep Remissions and Enhanced Safety in Adult B-ALL

By MedXY|Feb 18, 2026

The CART19-BE-02 phase 2 trial demonstrates that varnimcabtagene autoleucel, utilizing a unique fractionated dose escalation strategy, achieves an 84.4% MRD-negative complete response rate in adults with relapsed or refractory B-ALL while s

Nivolumab Redefines Long-Term Outcomes in Resected High-Risk Melanoma: 9-Year Insights from CheckMate 238
Dermatologyimmunotherapymelanoma

Nivolumab Redefines Long-Term Outcomes in Resected High-Risk Melanoma: 9-Year Insights from CheckMate 238

By MedXY|Feb 5, 2026

The final 9-year analysis of the CheckMate 238 trial confirms that adjuvant nivolumab provides a sustained recurrence-free survival advantage over ipilimumab in patients with resected high-risk melanoma, with 44% of patients remaining recur

Precision Immunotherapy in Type 1 Diabetes: Baseline Beta-Cell Function as a Predictive Biomarker for Abatacept Efficacy
Diabetes & EndocrinologyAbataceptBeta-cell function

Precision Immunotherapy in Type 1 Diabetes: Baseline Beta-Cell Function as a Predictive Biomarker for Abatacept Efficacy

By MedXY|Feb 3, 2026

A post-hoc analysis reveals that Abatacept significantly delays progression to Stage 2 or 3 Type 1 Diabetes specifically in individuals with higher baseline insulin secretion, marking a breakthrough in precision immunotherapy for early-stag

Camrelizumab Plus Chemotherapy Sets a New Five-Year Survival Benchmark in Recurrent or Metastatic Nasopharyngeal Carcinoma
newscamrelizumabimmunotherapy

Camrelizumab Plus Chemotherapy Sets a New Five-Year Survival Benchmark in Recurrent or Metastatic Nasopharyngeal Carcinoma

By MedXY|Jan 30, 2026

A secondary analysis of the CAPTAIN-1st trial reveals that adding camrelizumab to first-line chemotherapy significantly improves five-year overall survival in RM-NPC, with a 37.8% survival rate and notable benefits linked to rapid EBV DNA c

Dual-Action IgY and Cerium Oxide Nanofibrous Dressings Accelerate Scarless Healing in Infected Wound Models
Dermatologydermatologyimmunotherapy

Dual-Action IgY and Cerium Oxide Nanofibrous Dressings Accelerate Scarless Healing in Infected Wound Models

By MedXY|Jan 29, 2026

Researchers have developed a novel P/G@IYCe dressing combining yolk immunoglobulins and cerium oxide nanoparticles. This synergy effectively neutralizes bacterial pathogens and reactive oxygen species, facilitating rapid, high-quality skin

Optimizing Anti-GD2 Immunotherapy: Dinutuximab Beta Redefines Survival in Relapsed and High-Risk Neuroblastoma
newsDinutuximab Betaimmunotherapy

Optimizing Anti-GD2 Immunotherapy: Dinutuximab Beta Redefines Survival in Relapsed and High-Risk Neuroblastoma

By MedXY|Jan 20, 2026

Recent clinical trials establish dinutuximab beta as a cornerstone of neuroblastoma therapy, demonstrating significant survival benefits when combined with chemotherapy in relapsed cases, while clarifying that adding Interleukin-2 to standa

CYTOscore: A Triple-Cytokine Signature Predicts Survival and Response to Chemoradiotherapy Plus Anti-PD-1 in Esophageal Squamous Cell Carcinoma
GastroenterologybiomarkersCytokines

CYTOscore: A Triple-Cytokine Signature Predicts Survival and Response to Chemoradiotherapy Plus Anti-PD-1 in Esophageal Squamous Cell Carcinoma

By MedXY|Jan 19, 2026

A new serum cytokine-based risk score (CYTOscore) utilizing IL-8, CCL3, and CCL4 identifies ESCC patients likely to benefit from chemoradiotherapy combined with toripalimab, offering a non-invasive tool for personalized immunotherapy and pr

Neoadjuvant Lenvatinib Plus Pembrolizumab Achieves Robust Pathological Complete Response in Resectable Merkel Cell Carcinoma
Dermatologyimmunotherapylenvatinib

Neoadjuvant Lenvatinib Plus Pembrolizumab Achieves Robust Pathological Complete Response in Resectable Merkel Cell Carcinoma

By MedXY|Jan 19, 2026

A Phase II trial demonstrates that combining lenvatinib with pembrolizumab prior to surgery in Merkel cell carcinoma results in a 57.7% pathological complete response rate, suggesting a highly effective new strategy for managing resectable

Durable Survival and Enhanced Downstaging: Long-term Insights from the NEOpredict-Lung Trial on Preoperative PD-1 and LAG-3 Blockade
newsclinical trialsimmunotherapy

Durable Survival and Enhanced Downstaging: Long-term Insights from the NEOpredict-Lung Trial on Preoperative PD-1 and LAG-3 Blockade

By MedXY|Jan 19, 2026

Extended follow-up of the NEOpredict-Lung trial demonstrates that short-course preoperative nivolumab, with or without relatlimab, yields high 3-year survival rates and significant nodal downstaging in resectable NSCLC, positioning dual che

Tafasitamab Plus R2 Regimen Sets a New Benchmark for Relapsed or Refractory Follicular Lymphoma: Insights from the inMIND Trial
Hematology-OncologyFollicular lymphomaimmunotherapy

Tafasitamab Plus R2 Regimen Sets a New Benchmark for Relapsed or Refractory Follicular Lymphoma: Insights from the inMIND Trial

By MedXY|Jan 14, 2026

The Phase 3 inMIND trial demonstrates that adding tafasitamab to lenalidomide and rituximab (R2) significantly improves progression-free survival in patients with relapsed or refractory follicular lymphoma, reducing the risk of disease prog

Serplulimab Plus Chemotherapy Sustains Survival Advantage in ES-SCLC: Insights from the ASTRUM-005 Trial and Novel Biomarker Profiles
newsbiomarkersimmunotherapy

Serplulimab Plus Chemotherapy Sustains Survival Advantage in ES-SCLC: Insights from the ASTRUM-005 Trial and Novel Biomarker Profiles

By MedXY|Jan 14, 2026

Updated ASTRUM-005 results confirm serplulimab’s significant survival benefit in extensive-stage small-cell lung cancer (15.8 vs. 11.1 months). Exploratory analyses identify a 15-protein signature and RB1/Notch mutations as potential

Prev
3 / 9
12345…9
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities